Revolo Biotherapeutics
Revolo Biotherapeutics is a clinical-stage biopharmaceutical company developing '1104 and '1805, two platform drug candidates that restore immune homeostasis upstream to treat allergic and autoimmune diseases including eosinophilic esophagitis, rheumatoid arthritis, and ulcerative colitis.
- Company typePrivate
- Founded2011
- HeadquartersCambridge, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Revolo Biotherapeutics does
Revolo Biotherapeutics is a privately held, clinical-stage biopharmaceutical company developing two platform drug candidates, '1104 and '1805, for serious allergic and autoimmune diseases. The company's core technology targets immune homeostasis upstream in the immune cascade — simultaneously upregulating T and B regulatory cells while downregulating effector T cells — rather than suppressing inflammation downstream after it has occurred. This disease-agnostic, dual-arm mechanism is intended to deliver rapid and prolonged therapeutic effect without the broad immune suppression that characterizes existing therapies, which carry risks of serious infections and life-threatening side effects.
'1104 is a first-in-class immunomodulatory peptide currently in Phase 2 development for eosinophilic esophagitis (EoE), with planned Phase 2 studies in atopic dermatitis, asthma, allergic rhinitis, and other eosinophilic GI disorders. A sublingual tablet formulation was accelerated into the clinic in August 2025 following positive preclinical data, with clinical entry expected in 2026. '1805 is a biologic protein that completed a Phase 2a trial in rheumatoid arthritis demonstrating rapid onset (week 3) and sustained 12-week remission from a single intravenous dose; additional Phase 2 trials are planned in ulcerative colitis and non-infectious uveitis. Both candidates have completed five Phase 1-2 studies with favorable safety profiles and no evidence of immune suppression.
Revolo is pre-revenue and monetizes only through future pharmaceutical partnerships, licensing deals, or product commercialization with larger pharma companies upon successful clinical development and regulatory approval. The company is headquartered in Gaithersburg, Maryland with a UK entity (Revolo Biotherapeutics Limited) in Great Shelford, Cambridgeshire, and is backed by Morningside Venture Capital, 24 Haymarket, and Metellus AG. Current operating status is active with a senior leadership team spanning clinical development, regulatory affairs, CMC, clinical operations, quality, and investor relations.
Revolo Biotherapeutics firmographics
Firmographics- Name
- Revolo Biotherapeutics
- Legal name
- Revolo Biotherapeutics Limited
- Website
- https://revolobio.com
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Revolo Biotherapeutics is a clinical-stage biopharmaceutical company developing '1104 and '1805, two platform drug candidates that restore immune homeostasis upstream to treat allergic and autoimmune diseases including eosinophilic esophagitis, rheumatoid arthritis, and ulcerative colitis.
- Ownership category
- akta.pro rank
Revolo Biotherapeutics industry classification
Industry- Product category
- Biopharmaceutical Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Immunology & Inflammation Pharmaceuticals (HLAIAAAD)
- akta.pro secondary industries
- Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics) (HLAAAGAL), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Recombinant Protein Therapeutics (enzymes, hormones, growth factors) (HLAAAAAB)
Keywords
Where Revolo Biotherapeutics is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
Revolo Biotherapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure
Revenue model
- Biopharmaceutical Development: Pre-revenue clinical-stage biotech company developing novel therapeutics. Revenue generation anticipated through future product commercialization, licensing deals, or partnerships with larger pharmaceutical companies upon successful clinical development and regulatory approval.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Revolo Biotherapeutics product offering
Product offeringCore offering
Revolo Biotherapeutics is a clinical-stage biopharmaceutical company developing two proprietary drug candidates — '1104 (an immunomodulatory peptide) and '1805 (a biologic protein) — that restore immune homeostasis by targeting the immune system upstream to treat allergic and autoimmune diseases. The candidates are being advanced through Phase 2 clinical trials for eosinophilic esophagitis, atopic dermatitis, rheumatoid arthritis, ulcerative colitis, and other immune-mediated conditions.
Product overview
Revolo Biotherapeutics is a clinical-stage biopharmaceutical company developing two platform drug candidates ('1104 and '1805) for allergic and autoimmune diseases. '1104 is an immunomodulatory peptide in Phase 2 development for eosinophilic esophagitis, atopic dermatitis, asthma, and other allergic conditions, with a sublingual formulation advancing to clinical testing in 2026. '1805 is a biologic protein in Phase 2 development for rheumatoid arthritis and ulcerative colitis. Both candidates work upstream in the immune cascade to restore immune homeostasis without suppressing the immune system, offering potential first-line therapy options with differentiated safety profiles.
Differentiator
Problem solved
Functional benefit
Products and services
- '1104 (IRL201104) A first-in-class immunomodulatory peptide drug candidate that restores immune homeostasis by uniquely impacting both the regulatory and effector arms of the immune system. '1104 upregulates T and B regulatory cells while downregulating effector T cells without causing broad immune suppression, being developed for eosinophilic esophagitis, atopic dermatitis, asthma, and other allergic diseases.
- '1805 (IRL201805) A biologic drug candidate that alters immune tolerance through APC modification and Treg activation. '1805 has demonstrated long-term anti-inflammatory effects, reduction in fibrosis, cartilage destruction, and bone erosion in preclinical models, with rapid onset and sustained remission after a single IV dose in Phase 2a rheumatoid arthritis, and is also being developed for ulcerative colitis.
- '1104 Sublingual Tablet Formulation Sublingual (placed under the tongue) tablet formulation of '1104 achieving rapid and extensive systemic exposure with positive results across multiple clinical measures in preclinical atopic dermatitis studies, offering a patient-friendly oral alternative to injection routes for allergic disease treatment.
Quantifiable outcome
- Phase 2a trial in eosinophilic esophagitis met primary endpoint, reducing key inflammatory cells and leading to improved patient symptoms
- +3 more outcomes
Companies that use Revolo Biotherapeutics
Customer profileSegments9 records
Ideal customer profiles1 record
Revolo Biotherapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Revolo Biotherapeutics partnerships and signals
Strategic signalScale indicators4 records
Recent moves7 records
Expansion highlights5 records
Revolo Biotherapeutics competitors and assessment
Company assessmentDirect peers
- Allakos: Clinical-stage immunology biotech developing therapeutics for eosinophilic and allergic diseases, including EoE — directly overlapping with Revolo's '1104 eosinophilic esophagitis program and target physician audience.
- Arcutis Biotherapeutics: Dermatology-focused biopharma with late-stage assets in atopic dermatitis and other inflammatory skin conditions, directly competing in one of Revolo's lead '1104 target indications with similar Phase 2/3 clinical-stage assets.
- Tarsus Pharmaceuticals: Clinical-stage biopharma developing immunomodulatory therapeutics for inflammatory and immunology indications, with comparable size, stage, and partnering-driven business model to Revolo.
- Aurinia Pharmaceuticals: Commercial-stage autoimmune biotech (voclosporin in lupus nephritis) with comparable immunology focus and board overlap (Revolo director Peter Greenleaf is Aurinia's former CEO); provides a benchmarking point for clinical-stage-to-commercial immunology companies.
Emerging players
- Evommune: Early-stage immunology company developing differentiated therapies for atopic dermatitis and other immune-mediated diseases, with overlapping target indications and similar mechanism-of-action ambition to Revolo.
Broad incumbents
- Incyte Corporation: Established mid-cap biopharma with deep immunology/inflammation franchise (JAK inhibitors such as ruxolitinib/opzelura) competing across several of Revolo's target indications; benchmark for commercial-scale immunology competitors.
- Regeneron Pharmaceuticals: Co-developer of Dupixent (dupilumab) with Sanofi, the dominant biologic in atopic dermatitis and other type 2 inflammatory indications targeted by Revolo's '1104 — the primary commercial benchmark for any AD entrant.
- Amgen: Developer of Tezspire (tezepelumab) for severe asthma and other inflammation biologics (e.g., Otezla), competing in adjacent allergic/autoimmune indications targeted by Revolo and representing a likely large-pharma partner archetype.
Others
- Rocket Pharmaceuticals: Clinical-stage gene therapy biotech where Revolo Chairman David Southwell serves on the board; comparable as a small-cap clinical-stage US-listed biotech in the broader immunology/rare-disease ecosystem, useful for governance and capital-markets benchmarking.
- TScan Therapeutics: Clinical-stage T cell receptor biotech previously led by Revolo Chairman David Southwell; comparable as a small clinical-stage US biotech with immunology-adjacent pipeline and similar governance profile.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Revolo Biotherapeutics social profiles
Digital presenceRevolo Biotherapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Revolo Biotherapeutics leadership team
Management profileNumber of profiles
Profiles18 records
Revolo Biotherapeutics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Revolo Biotherapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Revolo Biotherapeutics
What does Revolo Biotherapeutics do?
Revolo Biotherapeutics is a clinical-stage biopharmaceutical company developing two proprietary drug candidates — '1104 (an immunomodulatory peptide) and '1805 (a biologic protein) — that restore immune homeostasis by targeting the immune system upstream to treat allergic and autoimmune diseases. The candidates are being advanced through Phase 2 clinical trials for eosinophilic esophagitis, atopic dermatitis, rheumatoid arthritis, ulcerative colitis, and other immune-mediated conditions.
Is Revolo Biotherapeutics a public or private company?
Revolo Biotherapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Revolo Biotherapeutics founded?
Revolo Biotherapeutics was founded in 2011. It employs 11 to 50 people.
Where is Revolo Biotherapeutics based?
Revolo Biotherapeutics is headquartered in Cambridge, United Kingdom, in the Europe region.
How does Revolo Biotherapeutics make money?
One revenue line is on record: biopharmaceutical Development.
Who are Revolo Biotherapeutics's main competitors?
Direct peers on record are Allakos, Arcutis Biotherapeutics, Tarsus Pharmaceuticals and Aurinia Pharmaceuticals. Evommune is listed as an emerging player. Broad incumbents are Incyte Corporation, Regeneron Pharmaceuticals and Amgen. Others are Rocket Pharmaceuticals and TScan Therapeutics.
Does Revolo Biotherapeutics have an API?
No public API is recorded for Revolo Biotherapeutics.
What industry is Revolo Biotherapeutics in?
Revolo Biotherapeutics's product category is Biopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAIAAAD, Immunology & Inflammation Pharmaceuticals, with a secondary code of HLAAAGAL, Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics). Its NAICS code is 325414 and its SIC code is 2836.